| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | salermide | CTRPv2 | pan-cancer | AAC | -0.0036 | 0.9 |
| mRNA | navitoclax:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0027 | 0.9 |
| mRNA | Parthenolide | CTRPv2 | pan-cancer | AAC | -0.0028 | 0.9 |
| mRNA | Sildenafil | CTRPv2 | pan-cancer | AAC | -0.0026 | 0.9 |
| mRNA | dexamethasone | CTRPv2 | pan-cancer | AAC | 0.0022 | 0.9 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | 0.0024 | 1 |
| mRNA | PD 153035 | CTRPv2 | pan-cancer | AAC | -0.0026 | 1 |
| mRNA | ouabain | CTRPv2 | pan-cancer | AAC | 0.0021 | 1 |
| mRNA | NVP-231 | CTRPv2 | pan-cancer | AAC | 0.0017 | 1 |
| mRNA | KHS101 | CTRPv2 | pan-cancer | AAC | -0.002 | 1 |